Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL SA vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics at higher concentrations.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
55-60% bound, primarily to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.45 L/kg (0.3-0.7 L/kg). Reflects distribution into total body water, with lower Vd in obese patients when adjusted for ideal body weight.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 100% for choline theophyllinate (Choledyl) as it is completely absorbed; the sustained-action formulation (Choledyl SA) has equivalent bioavailability to immediate-release.
Oral: 40-50%; Inhalation: 20-30%
GFR 50-80 m L/min: 50% of usual dose; GFR <50 m L/min: avoid use due to accumulation of choline and theophylline.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: 50% of usual dose; Child-Pugh B: 25% of usual dose; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not recommended for use in children under 12 years due to lack of safety data.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initiate at 400 mg every 12 hours; titrate slowly with monitoring of serum theophylline levels due to reduced clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Theophylline has narrow therapeutic index; serum levels must be monitored to avoid toxicity (toxicity risk increases above 20 mcg/m L).,Concomitant use with other xanthines may potentiate toxicity.,Use with caution in patients with cardiovascular disease (e.g., arrhythmias), seizure disorders, hepatic impairment, or peptic ulcer disease.,Drug interactions: CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) increase theophylline levels; CYP1A2 inducers (e.g., phenytoin, rifampin) decrease levels.,Risk of hypokalemia and hypophosphatemia with high doses or prolonged use.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation.,Acute myocardial infarction with bradycardia or tachyarrhythmias.,Active seizure disorder not controlled with anticonvulsant therapy.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid high-fat meals that may alter absorption. Caffeine (coffee, tea, cola, chocolate) potentiates adverse effects. Charcoal-broiled foods can increase theophylline metabolism.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unknown; use only if benefit outweighs risk. Second/third trimester: possible fetal tachycardia and irritability; avoid near term due to potential neonatal apnea, jitteriness, and withdrawal symptoms.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Infant may receive 1-10% of maternal dose. Monitor infant for irritability, insomnia, and tachycardia. Use caution; benefit should outweigh risk. Alternative agents may be preferred.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy may reduce theophylline clearance (especially third trimester) due to decreased hepatic metabolism and increased volume of distribution. Dose reduction may be needed; monitor levels and adjust to maintain therapeutic range. Postpartum clearance increases rapidly; adjust dose downward after delivery to avoid toxicity.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Choledyl SA (oxtriphylline) is a sustained-release theophylline salt. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active peptic ulcer disease and seizure disorders. Cigarette smoking induces metabolism, requiring dose adjustments. Use with caution in patients with hepatic impairment, cardiac disease, or hypothyroidism.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid excessive consumption of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Notify your doctor if you experience nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop taking abruptly; dose tapering may be needed.,Inform your doctor if you smoke or stop smoking, as dose adjustments may be required.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL SA vs AEROLATE III, answered by our medical review team.
CHOLEDYL SA is a Bronchodilator that works by Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL SA and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL SA is: 400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL SA and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL SA is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unkn. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.